Biomarker-Bottleneck_990x120.png
If you have already registered, please check your email for the webinar link.

Event Overview

In recent years, an avalanche of new compounds has been developed for the treatment of cancer with immunotherapy. However, novel biomarkers are required to guide treatment with these new compounds. The complexity of cancer and the immune response means predictive biomarkers for immuno-oncology can differ vastly between people and cancer subtypes. New approaches for biomarker discovery include using next-generation gene expression profiling, which allows patient-level biomarker determination, as well as multiplex spatial protein profiling to identify protein targets including immune cell markers and checkpoint proteins. To delve deeper into the biomarker bottleneck, The Scientist is bringing together a panel of experts to discuss their research and provide insight into how this issue is being overcome.

Topics to be Covered
  • Assessing heterogeneity of immune cell infiltration in tumors to predict response to cancer immunotherapy
  • Mapping the landscape of tumors
Wednesday, January 23, 2019
 
2:30 - 4:00 PM Eastern Time


Speaker

Alice Kamphorst.png
Alice O. Kamphorst, PhD
Assistant Professor, Dept. of Oncological Sciences
Precision Immunology Institute
Icahn School of Medicine at Mount Sinai

Evisa Gjini.png
Evisa Gjini, PhD
Associate Director (Clinical Biomarkers / ImmunoProfile), Dept. of Pathology
Brigham and Women's Hospital
Dana Farber Cancer Institute


biolegend logobox.png

Register Now

The Biomarker Bottleneck in Immuno-oncology: Understanding to Overcome

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.